Cargando…

1249. Genetic Evidence That Gepotidacin Shows Well-balanced Dual Targeting against DNA Gyrase And Topoisomerase IV in Neisseria gonorrhoeae

BACKGROUND: Gepotidacin (GEP) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor targeting both bacterial DNA gyrase and topoisomerase IV by a different mechanism from fluoroquinolone antibiotics. Although in vitro frequency of resistance to GEP in Neisseria gonorrhoeae (NG) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Pan, Ingraham, Karen, Min, Sharon, Scangarella-Oman, Nicole, Rittenhouse, Steve, Huang, Jianzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776390/ http://dx.doi.org/10.1093/ofid/ofaa439.1433

Ejemplares similares

Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae
por: Scangarella-Oman, Nicole E., et al.
Publicado: (2018)

Actions of a Novel Bacterial Topoisomerase Inhibitor against Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks
por: Dauda, Soziema E., et al.
Publicado: (2023)

1438. Dissecting the Multifaceted Nature of Antibiotic Resistance in Clinical Isolates of Neisseria gonorrhoeae by Natural Transformation
por: Huang, Jianzhong, et al.
Publicado: (2020)

Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea
por: Scangarella-Oman, Nicole E, et al.
Publicado: (2023)

Activities of gyrase and topoisomerase IV on positively supercoiled DNA
por: Ashley, Rachel E., et al.
Publicado: (2017)

724. The In Vitro Activity of Gepotidacin and Comparator Agents Against Anaerobic Bacterial Isolates
por: Hackel, Meredith, et al.
Publicado: (2019)

Epidemiology of Neisseria gonorrhoeae Gyrase A Genotype, Los Angeles, California, USA
por: Bhatti, Ashima A., et al.
Publicado: (2017)

In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes
por: Hackel, Meredith A., et al.
Publicado: (2022)

In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium
por: Jensen, Jørgen Skov, et al.
Publicado: (2020)

701. Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods
por: Arends, S J Ryan, et al.
Publicado: (2019)

Distribution of gyrase and topoisomerase IV on bacterial nucleoid: implications for nucleoid organization
por: Hsu, Ya-Han, et al.
Publicado: (2006)

714. Analysis of the Effect of Urine on the In Vitro Activity of Gepotidacin and Levofloxacin Against Escherichia coli, Staphylococcus epidermidis, and Staphylococcus saprophyticus
por: Koeth, Laura M, et al.
Publicado: (2019)

1262. Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019
por: Arends, S J Ryan, et al.
Publicado: (2020)

Development of Cas13a-based Assays for Neisseria gonorrhoeae Detection and Gyrase A Determination
por: Allan-Blitz, Lao-Tzu, et al.
Publicado: (2023)

Development of Cas13a-based assays for Neisseria gonorrhoeae detection and gyrase A determination
por: Allan-Blitz, Lao-Tzu, et al.
Publicado: (2023)

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
por: Grossman, Scott, et al.
Publicado: (2023)

What makes a type IIA topoisomerase a gyrase or a Topo IV?
por: Hirsch, Jana, et al.
Publicado: (2021)

Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections
por: Scangarella-Oman, Nicole E., et al.
Publicado: (2022)

In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections
por: Scangarella-Oman, Nicole E., et al.
Publicado: (2020)

Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020)
por: Arends, S. J. Ryan, et al.
Publicado: (2023)

1482. Microbiological Analysis from a Phase II Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections
por: Scangarella-Oman, Nicole, et al.
Publicado: (2019)

Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
por: O'Riordan, William, et al.
Publicado: (2017)

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
por: VanScoy, Brian D., et al.
Publicado: (2021)

1440. The Genetic Basis for a Neisseria gonorrhoeae Clinical Isolate That Contains mtrR(-79) Mutation But Is Highly Susceptible to Antibiotics Effluxed by the Mtr Pump System
por: Huang, Jianzhong, et al.
Publicado: (2020)

Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants
por: Perry, Caroline, et al.
Publicado: (2022)

Neisseria gonorrhoeae
por: Ehrhard, Ingrid
Publicado: (2009)

High-throughput assays for DNA gyrase and other topoisomerases
por: Maxwell, Anthony, et al.
Publicado: (2006)

DNA Gyrase and Topoisomerase IV Mutations and their effect on Quinolones Resistant Proteus mirabilis among UTIs Patients
por: Abdelkreem, Randa H, et al.
Publicado: (2020)

Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study
por: Perry, Caroline R., et al.
Publicado: (2023)

1479. Clinical Efficacy and Safety Analysis Evaluating Oral Gepotidacin (GSK2140944) from a Phase IIa Study in the Treatment of Uncomplicated Urinary Tract Infections
por: Overcash, J Scott, et al.
Publicado: (2019)

The balance between gyrase and topoisomerase I activities determines levels of supercoiling, nucleoid compaction, and viability in bacteria
por: García-López, Míriam, et al.
Publicado: (2023)

1480. Plasma and Urine Pharmacokinetic Analysis of Gepotidacin (GSK2140944) Following BID Oral Dosing in a Phase IIa Study for Treatment of Uncomplicated Urinary Tract Infections
por: Zimmerman, Eric I, et al.
Publicado: (2019)

1281. Longitudinal and Spatial Variation in the Human Microbiome in a Phase 2a Clinical Study of Gepotidacin in Adult Females with Uncomplicated Urinary Tract Infection
por: Nuzzo, Andrea, et al.
Publicado: (2020)

Direct observation of helicase–topoisomerase coupling within reverse gyrase
por: Yang, Xi, et al.
Publicado: (2020)

1075. In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized Fluoroquinolone Resistant Subsets
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats
por: Fishman, Cindy, et al.
Publicado: (2022)

Neisseria gonorrhoeae Infections
por: Suay-García, Beatriz, et al.
Publicado: (2020)

Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)
por: Nuzzo, Andrea, et al.
Publicado: (2021)

High Resolution Melting Analysis for Rapid Mutation Screening in Gyrase and Topoisomerase IV Genes in Quinolone-Resistant Salmonella enterica
por: Ngoi, Soo Tein, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q39ttp5o3cpvnt4nngbv7s9lii